rhIL-15
Phase 2Small molecule
rhIL-15 is one of 101 small molecule programs targeting Leukemia. It is currently in Phase 2.
3
Indications
5
Total Trials
1
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Fludara
SanofiPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rituxan
RochePhase 3
Idamycin
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Neoral
NovartisPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Refractory Cancer1 trial
Neuroblastoma1 trial
Relapsed/Refractory1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhIL-15. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)